STOCK TITAN

Cingulate adds Maxim Group to up to $100M stock offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Cingulate Inc. (CING) amended its at-the-market sales agreement to add Maxim Group LLC as an agent alongside A.G.P. Under the existing agreement, the company may sell common stock from time to time for an aggregate offering price of up to $100 million. Cingulate said it substantially completed manufacturing work addressing FDA chemistry, manufacturing and controls requests for CTx-1301 and expects to resubmit its NDA between December 2026 and January 2027. The June 1, 2026 Complete Response Letter identified CMC information requests and did not identify clinical safety or efficacy concerns.

At September 30, 2026, cash and cash equivalents were approximately $23.2 million and working capital was approximately $18.8 million. Cingulate believes its cash will fund operations into mid-2027 under its current business plan. Third-quarter net loss was $7.7 million, compared with $7.3 million a year earlier; nine-month net loss was $22.9 million, compared with $16.2 million. Nine-month SG&A was $14.2 million, up 116.6% from $6.6 million.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointNine-month net loss was $22.9 million, compared with $16.2 million in 2025.

Filing Explained

For the first nine months of 2026, the company reports $22.5 million raised through its ATM agreement and Lincoln Park purchase agreement together, against $20.4 million used for operations; it does not break out ATM proceeds separately.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
ATM agreement aggregate offering price Up to $100 million Existing agreement permits common stock sales from time to time through sales agents.
Cash and cash equivalents Approximately $23.2 million As of September 30, 2026.
Working capital Approximately $18.8 million As of September 30, 2026.
Cash runway Into mid-2027 Company estimate under its current business plan.
Third-quarter net loss $7.7 million Three months ended September 30, 2026; compared with $7.3 million in 2025.
Nine-month net loss $22.9 million Nine months ended September 30, 2026; compared with $16.2 million in 2025.
Nine-month SG&A expenses $14.2 million Nine months ended September 30, 2026; up 116.6% from $6.6 million in 2025.
Expected NDA resubmission Between December 2026 and January 2027 CTx-1301.
At-the-Market Agreement financial
"may offer and sell common stock from time to time"
An at-the-market agreement is a standing arrangement that lets a company sell newly issued shares directly into the open market through a broker at prevailing market prices, rather than in a single large offering. Like putting a tap on supply that can be turned on gradually, it matters to investors because it provides flexible access to cash and can increase the number of shares available to trade, which may affect share supply and market liquidity.
chemistry, manufacturing and controls regulatory
"FDA’s chemistry, manufacturing and controls information requests"
Chemistry, manufacturing and controls (CMC) is the package of technical information that explains how a drug or biologic is made, tested and kept consistent, submitted to regulators to demonstrate the product’s safety, purity and reliable production. Investors care because robust CMC lowers the risk of manufacturing delays, regulatory rejection or costly recalls — think of it as the product’s recipe and kitchen controls that determine whether a medicine can be scaled, sold and generate revenue.
Complete Response Letter regulatory
"The FDA issued a Complete Response Letter for the CTx-1301 NDA"
A complete response letter is an official communication from a drug or medical-device regulator, such as the U.S. Food and Drug Administration (FDA), telling a company that a marketing application cannot be approved in its current form and listing the specific deficiencies to be fixed. For investors it matters because it pauses or delays a product’s path to market—like a building inspector issuing a list of repairs before a certificate of occupancy—affecting revenue timing, costs and stock value.
Class 1 or Class 2 resubmission regulatory
"expected to classify it as a Class 1 or Class 2 resubmission"
505(b)(2) pathway regulatory
"CTx-1301 is being evaluated for ADHD under the FDA’s 505(b)(2) pathway"
A 505(b)(2) pathway is a U.S. regulatory route that lets a drug developer get approval by relying in part on existing clinical data or published studies instead of repeating every test. Think of it as building on someone else’s homework to shorten development time and cost. For investors, it signals potentially faster, lower‑risk market entry and a chance for competitive protection compared with starting brand‑new drug approvals.
Precision Timed Release technical
"Cingulate’s proprietary Precision Timed Release platform"
A precision timed release is a drug formulation designed so the active ingredient becomes available at specific, predetermined times after a patient takes a dose, rather than all at once. Like a timed sprinkler that waters different zones on schedule, it can improve how well a medicine works, reduce side effects, and make dosing more convenient—factors that affect regulatory approval, patent protection, market differentiation and ultimately a product’s commercial value for investors.
Research and development expenses, third quarter $2,910,660 Up 2.2% from $2,848,544 in 2025.
Research and development expenses, nine months $6,581,803 Down 15.3% from $7,772,109 in 2025.
Selling, general and administrative expenses, third quarter $4,580,358 Up 45.5% from $3,147,291 in 2025.
Selling, general and administrative expenses, nine months $14,247,412 Up 116.6% from $6,579,735 in 2025.
Net loss, third quarter $7,731,397 Compared with $7,341,062 in 2025.
Net loss, nine months $22,913,750 Compared with $16,177,001 in 2025.
Guidance

Cingulate believes cash and cash equivalents will fund operations into mid-2027 under its current business plan and expects to resubmit the CTx-1301 NDA between December 2026 and January 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does CING expect to resubmit the CTx-1301 NDA?

Cingulate expects to resubmit the NDA between December 2026 and January 2027. After receiving it, the FDA is expected to classify the resubmission as Class 1 or Class 2, which have review goals of two and six months, respectively.

How long does CING expect its cash to fund operations?

Cingulate believes its cash and cash equivalents will fund operations into mid-2027 under its current business plan, including costs associated with seeking regulatory approval for CTx-1301 and continuing its commercial-readiness build-out.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001862150 0001862150 2026-11-13 2026-11-13 0001862150 CING:CommonStockParValue0.0001PerShareMember 2026-11-13 2026-11-13 0001862150 CING:WarrantsExercisableForCommonStockMember 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

November 13, 2026

 

CINGULATE INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40874   86-3825535

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1901 W. 47th Place

Kansas City, KS 66205

(Address of principal executive offices) (Zip Code)

 

(913) 942-2300

(Registrant’s telephone number, including area code)

 

___________________________________________________________________

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001 per share   CING  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

Warrants, exercisable for common stock   CINGW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into Material Definitive Agreement

 

As previously disclosed, on March 24, 2026, Cingulate Inc. (the “Company”) entered into an ATM Sales Agreement, or the ATM Agreement, with A.G.P./Alliance Global Partners (“A.G.P.”) as sales agent (the “Agent”), pursuant to which the Company may offer and sell, our common stock, par value $0.0001 per share, or common stock, having an aggregate offering price of up to $100,000,000, from time to time, through the Agent.

 

On November 13, 2026, the Company entered into Amendment No. 2 to the ATM Agreement (the “Amendment”) with A.G.P. and Maxim Group LLC (“Maxim”) solely to add Maxim Group LLC as an Agent under the ATM Agreement. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 hereto.

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 13, 2026, Cingulate Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a regulatory update. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference. The information in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   Amendment No. 1 to ATM Agreement, by and among the Company, A.G.P. and Maxim, dated November 13, 2026
     
99.1   Press Release dated November 13, 2026
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CINGULATE INC.
     
Dated: November 13, 2026 By: /s/ Jennifer L. Callahan
  Name: Jennifer L. Callahan
  Title: Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission

 

Manufacturing Work Addressing FDA CMC Information Requests Substantially Completed

 

NDA Resubmission Expected Between December 2026 and January 2027

 

KANSAS CITY, Kan., Nov. 13, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended September 30, 2026, and announced that it has substantially completed the manufacturing work required to address the U.S. Food and Drug Administration’s (FDA) chemistry, manufacturing and controls (CMC) information requests for CTx-1301. The Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027.

 

“With the manufacturing work substantially complete, we are now finalizing the data and documentation needed to resubmit the NDA for CTx-1301, and we expect to do so by January 2027, potentially sooner,” stated Cingulate Chairman and CEO Shane J. Schaffer. “Importantly, the FDA’s Complete Response Letter did not raise any concerns about the clinical safety or efficacy of CTx-1301. We thank our shareholders for their patience and continued support as we work to bring this treatment to patients with ADHD.”

 

Regulatory Update: CTx-1301 NDA Resubmission Progress

 

On June 1, 2026, the FDA issued a Complete Response Letter (CRL) for the CTx-1301 (dexmethylphenidate HCl) NDA. The CRL identified specific requests for additional CMC information and did not identify any concerns regarding the clinical safety or efficacy of CTx-1301, the Company’s lead ADHD asset.

 

Since then, Cingulate and its contract development and manufacturing organization (CDMO), Bend Bioscience, have substantially completed the manufacturing work required to address the CMC requests in the CRL and are finalizing the supporting data and documentation for resubmission. As announced on November 9, 2026, the Company expects to resubmit the NDA between December 2026 and January 2027. After the FDA receives the resubmission, it is expected to classify it as a Class 1 or Class 2 resubmission, which carry review goals of two and six months, respectively.

 

Third Quarter Financial Results

 

Cash and Working Capital: As of September 30, 2026, Cingulate had approximately $23.2 million in cash and cash equivalents, compared to $11.0 million as of December 31, 2025. The increase was primarily driven by capital raised during the first nine months of 2026, including the close of a $12.0 million private placement in the first quarter and $22.5 million of capital raised on Cingulate’s At-the-Market Agreement with AGP and Purchase Agreement with Lincoln Park Capital, partially offset by $20.4 million in cash used for operations. As of September 30, 2026, Cingulate had approximately $18.8 million in working capital, an increase of $16.1 million as compared to December 31, 2025.

 

Under its current business plan, the Company believes its cash and cash equivalents will be sufficient to fund operations into mid-2027, including costs associated with seeking regulatory approval for CTx-1301, and continuing the build-out of commercial readiness capabilities.

 

R&D Expenses: Research and development expenses were $2.9 million for the three months ended September 30, 2026, an increase of 2.2% from $2.8 million for the three months ended September 30, 2025, driven primarily by higher drug manufacturing costs to address the CMC information requested in the FDA’s CRL, partially offset by lower clinical operations costs following the conclusion of clinical study activities in early 2025, the absence of regulatory costs incurred in the prior-year period in connection with preparing the CTx-1301 NDA, and lower personnel expenses. For the nine months ended September 30, 2026, R&D expenses were $6.6 million, a decrease of 15.3% from $7.8 million for the nine months ended September 30, 2025, driven primarily by lower clinical operations and regulatory costs, partially offset by increased manufacturing activities related to CTx-1301 following the CRL.

 

 

 

 

SG&A Expenses: Selling, general and administrative expenses (SG&A) were $4.6 million for the three months ended September 30, 2026, compared to $3.1 million for the three months ended September 30, 2025, an increase of 45.5%. For the nine months ended September 30, 2026, SG&A expenses were $14.2 million, compared to $6.6 million for the nine months ended September 30, 2025, an increase of 116.6%. The increases were driven primarily by the build-out of commercial readiness capabilities, including increased headcount and expanded market access, pricing, reimbursement and medical affairs activity conducted through Indegene, the Company’s commercialization partner.

 

Net Loss: Net loss was $7.7 million for the three months ended September 30, 2026, compared to $7.3 million for the three months ended September 30, 2025. For the nine months ended September 30, 2026, net loss was $22.9 million, compared to $16.2 million for the nine months ended September 30, 2025. The increases primarily reflect the higher SG&A expenses described above, partially offset in the third quarter by a smaller loss from the change in fair value of derivative and lower interest expense, and for the nine-month period by lower R&D expenses.

 

Cingulate Inc.

Consolidated Balance Sheet Data

 

   September 30,   December 31, 
   2026   2025 
Cash and cash equivalents  $23,185,900   $10,953,383 
Total assets  $28,150,677   $15,073,263 
Total liabilities  $7,383,547   $12,564,356 
Working Capital  $18,832,234   $1,695,633 
Accumulated deficit  $(155,288,781)  $(132,375,031)
Total stockholders’ equity  $20,767,130   $2,508,907 

 

Cingulate Inc.

Consolidated Statements of Operations

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Operating expenses:                    
Research and development  $2,910,660   $2,848,544   $6,581,803   $7,772,109 
Selling, general and administrative   4,580,358    3,147,291    14,247,412    6,579,735 
Operating loss   (7,491,018)   (5,995,835)   (20,829,215)   (14,351,844)
                     
Change in fair value of derivative   (69,323)   (772,169)   (1,235,366)   (1,016,682)
Interest and other income (expense), net   (171,056)   (573,058)   (849,169)   (808,475)
                     
Loss before income taxes   (7,731,397)   (7,341,062)   (22,913,750)   (16,177,001)
Income tax benefit (expense)   -    -    -    - 
                     
Net loss   (7,731,397)   (7,341,062)   (22,913,750)   (16,177,001)

 

About Attention Deficit/Hyperactivity Disorder (ADHD)

 

ADHD is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The estimated market size of the US ADHD market is approximately 100 million annual prescriptions. The condition is marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC, just 53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with 65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence is larger and growing faster than the child and adolescent segments combined.

 

 

 

 

About CTx-1301

 

CTx-1301 (dexmethylphenidate HCl) is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform to deliver three precisely timed releases of active medication across the day. This design aims to provide rapid onset of effect and entire active-day duration. CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway. In October 2025, the FDA accepted for review the NDA for CTx-1301 and assigned a PDUFA target action date of May 31, 2026. On June 1, 2026, the FDA issued a Complete Response Letter for the CTx-1301 NDA; the Company and its CDMO have since substantially completed the manufacturing work required to address the CMC requests, and the Company expects to resubmit the NDA between December 2026 and January 2026. There can be no assurance regarding the timing of any resubmission or whether approval will occur.

 

About Precision Timed Release™ (PTR™) Platform Technology

 

Cingulate is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition to Anxiety and ADHD.

 

About Cingulate Inc.

 

Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, the timing and outcome of any resubmission of the CTx-1301 NDA, market opportunity, competitive position, business strategies, potential growth opportunities, our expected cash runway, and anticipated capital needs and financing plans. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 18, 2026 and our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

 

Investor & Media Relations:

 

Thomas Dalton

Vice President, Corporate and Government Relations, Cingulate

tdalton@cingulate.com

(480) 529-5434

 

 

 

Filing Exhibits & Attachments

6 documents

Keep reading